FDA de­lays de­ci­sion on Stealth’s Barth syn­drome drug; Tar­getRx rais­es $50M

Plus, news about Val­ne­va and Ab&B Bio-Tech:

FDA de­lays de­ci­sion on Stealth Bio­Ther­a­peu­tics drug to April 29: The com­pa­ny’s elamipre­tide is be­ing de­vel­oped for Barth …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER